

**Filed On Behalf Of:**  
Novartis Pharmaceuticals Corporation

**By:**  
Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

BRECKENRIDGE PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

---

Case IPR2017-01592

Patent No. 8,410,131

---

**PATENT OWNER'S EXHIBIT LIST 2**

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2001</b>	Expert Declaration Of Howard A. Burris, III, M.D.	<b>Burriss Decl.</b>
<b>2002</b>	<i>Curriculum Vitae</i> Of Howard A. Burris, III, M.D.	<b>Burriss C.V.</b>
<b>2003</b>	Laughlin, E.H., <i>Coming To Terms With Cancer: A Glossary Of Cancer-Related Terms</i> , pages 4, 126, 140, 173-174, 188-190 (2002)	<b>Laughlin</b>
<b>2004</b>	Altman, R. & Sarg, M.J., <i>The Cancer Dictionary</i> , pages 51-52, 278 (1992)	<b>Altman</b>
<b>2005</b>	Sutcliffe, S.B. & Gospodarowicz, M.K., Chapter 25, "Primary Extranodal Lymphomas," <i>The Lymphomas</i> (Canellos, G.P. <i>et al.</i> eds. 1998)	<b>Sutcliffe 1998</b>
<b>2006</b>	Molina, A. & Pezner, R.D., Chapter 30, "Non-Hodgkin's Lymphoma," <i>Cancer Management: A Multidisciplinary Approach: Medical, Surgical, &amp; Radiation Oncology</i> , 4th Edition (Pazdur, R., <i>et al.</i> eds. 2000)	<b>Pazdur</b>

Exhibit	Description	Abbreviation
2007	Sutcliffe, S.B. & Gospodarowicz, M.K., "Clinical Features And Management Of Localized Extranodal Lymphomas," <i>Haematological Oncology</i> , Volume 2 pages 189-222 (Keating, A., <i>et al.</i> eds. 1992)	Sutcliffe 1992
2008	Lynch, C.F. & Cohen, M.B., "Urinary System," <i>Cancer</i> 75(1 Suppl.): 316-329 (1995)	Lynch & Cohen
2009	Ligato, S. <i>et al.</i> , "Benign Tumors And Tumor-Like Lesions Of The Adult Kidney Part I: Benign Renal Epithelial Neoplasms," <i>Adv. Anat. Pathol.</i> 6(1): 1-11 (1999)	Ligato
2010	Glenn, G.M. <i>et al.</i> , Chapter 75, "The Molecular Genetics Of Renal Cell Carcinoma," <i>Principles And Practice Of Genitourinary Oncology</i> (Raghavan, D., <i>et al.</i> eds. 1997)	Raghavan-Glenn
2011	Hyland, S. & Wilkinson, D., Chapter 14, "The Nurse Practitioner And The Organization Of Support Services For The Patient With Genitourinary Cancer," <i>Principles And Practice Of Genitourinary Oncology</i> (Raghavan, D., <i>et al.</i> eds. 1997)	Raghavan-Hyland

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2012</b>	Vasey, P.A., "Immunotherapy For Renal Carcinoma: Theoretical Basis And Current Standard Of Care," <i>Br. J. Clin. Pharmacol.</i> 50: 521-529 (2000)	<b>Vasey</b>
<b>2013</b>	Kawai, K., <i>et al.</i> , "Ex Vivo Gene Therapy Using Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Tumor Vaccines," <i>Mol. Urol.</i> 4(2): 43-46 (2000)	<b>Kawai</b>
<b>2014</b>	Adjei, A.A., "Signal Transduction Pathway Targets For Anticancer Drug Discovery," <i>Cur. Pharm. Design</i> 6: 361-378 (2000)	<b>Adjei</b>
<b>2015</b>	Gordon, M.S. <i>et al.</i> , "Phase I Safety And Pharmacokinetic Study Of Recombinant Human Anti-Vascular Endothelial Growth Factor In Patients With Advanced Cancer," <i>J. Clin. Oncol.</i> 19(3): 843-850 (2001)	<b>Gordon</b>
<b>2016</b>	Penn, I. & Starzl, T.E., "Immunosuppression And Cancer," <i>Transplant Proc.</i> 5(1): 943-947 (1973)	<b>Penn &amp; Starzl</b>
<b>2017</b>	January 19, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,537	

Exhibit	Description	Abbreviation
2018	January 27, 2016 Office Action, Prosecution File History Of U.S. Patent Application No. 13/893,589	
2019	October 17, 2006 Official Communication and February 26, 2007 Applicant Response (received February 27, 2007), Prosecution File History Of European Patent Application No. 01 903 095.6-2112 (International Application No. PCT/US01/01537)	
2020	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Christina Schwarz Under 37 C.F.R. § 42.10	
2021	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Charlotte Jacobsen Under 37 C.F.R. § 42.10	
2022	Declaration In Support Of Patent Owner Novartis's Motion For <i>Pro Hac Vice</i> Admission Of Susanne L. Flanders Under 37 C.F.R. § 42.10	

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.